Morgan Stanley initiated coverage of Mirum Pharmaceuticals with an Overweight rating and $60 price target. The analyst expects continued launch momentum for the company’s lead program, Livmarli in Alagille syndrome, with near-term opportunity for label expansion and multiple catalysts. The firm says Mirum is a leading rare liver disease company with a track record of success.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MIRM:
- Mirum Pharmaceuticals price target lowered to $60 from $63 at H.C. Wainwright
- Mirum Pharmaceuticals reports Q3 EPS (57c), consensus (65c)
- Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
- Cantor starts Mirum at Overweight on inhibitor portfolio expansion
- Mirum Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald